Clinical Trial Search

Primary: Overall Survival (OS) — 14.6; 13.0 Months — p=0.0180

Primary: Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 — 140 Participants

Primary: Incidence of Delirium — 5; 16 Participants — p=0.029

Primary: Number of Participants With Postpartum Hemorrhage (PPH) — 409; 399; 111; 125 Participants — p=0.33

Primary: Clot Degradation at 24 Hours Post-operatively — 0.65; 0.88; 0.78; 0.46 microns per hour

Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) — 70.0; 63.3 percentage of participants

Primary: Progression-Free Survival (PFS) — 12.32; 22.57 months — p=<.0001

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 23.6; 14.9 Percentage of participants — p=<0.0001

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 54.5 percentage of participants

Primary: Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation — 460; 7; 41 Participants

Primary: Safety Endpoint: Number of Subjects With SAEs, AEs Leading to Withdrawal From the Study, NOCDs, AESIs and Medically Attended AEs. — 7; 4; 0; 0 Participants

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint) — 95.0; 91.0 percentage of…

Primary: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume — 3; 5 Participants

Primary: Number of Participants With Infectious Complications — 6; 7; 6; 8 Participants

Primary: Time to Clinical Improvement — 12; 12; 11; 12 days